folder

Cellular senescence in cancer treatment: friend or foe?

Authors

  • P. Kahlem
  • B. Doerken
  • C.A. Schmitt

Journal

  • Journal of Clinical Investigation

Citation

  • J Clin Invest 113 (2): 169-174

Abstract

  • Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.


DOI

doi:10.1172/JCI20784